IRWD — Ironwood Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	428	390	414	411	443
Cost of Revenue
Gross Profit	405	386	414	411	—
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	339	247	181	160	1,388
Operating Profit	89.1	143	232	250	-945
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	58.9	109	201	252	-948
Provision for Income Taxes
Net Income After Taxes	58.9	106	528	175	-1,032
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	21.5	106	528	175	-1,002
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	21.5	106	528	180	-1,002
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.552	0.743	3.21	0.964	0.676